Doe v. Irvine Scientific Sales Co., Inc.

7 F. Supp. 2d 737, 1998 U.S. Dist. LEXIS 8741, 1998 WL 309217
CourtDistrict Court, E.D. Virginia
DecidedJune 8, 1998
DocketCIV. A. 2:97CV1167
StatusPublished
Cited by2 cases

This text of 7 F. Supp. 2d 737 (Doe v. Irvine Scientific Sales Co., Inc.) is published on Counsel Stack Legal Research, covering District Court, E.D. Virginia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Doe v. Irvine Scientific Sales Co., Inc., 7 F. Supp. 2d 737, 1998 U.S. Dist. LEXIS 8741, 1998 WL 309217 (E.D. Va. 1998).

Opinion

OPINION AND ORDER

CLARKE, District Judge.

This matter is presently before the Court on Defendants’, Irvine Scientific Sales Company, Inc.’s and Baxter Healthcare Corporation’s, Motions to Dismiss pursuant to Fed. R.Civ.P. 12(b)(6), and Plaintiffs’, John and Jane Doe’s, Motion for a Protective Order. For the following reasons, the Court GRANTS the Defendants’ motions and DENIES the Plaintiffs’ motion.

I.

All of the following facts are taken from the Plaintiffs’ First Amended Complaint. Plaintiffs John and Jane Doe (pseudonyms), bring this class action and allege that during in-vitro fertilization procedures, they have been exposed to, or have had their sperm, eggs, embryos, or other reproductive tissues exposed to certain lots of the product Human Albumin. This blood-derived product was manufactured by Defendant Baxter Healthcare Corporation, and sold and distributed by Defendant Irvine Scientific Sales Company, Inc. Plaintiffs are Florida residents and bring this suit pursuant to the Court’s diversity jurisdiction which is uncontested. See 28 U.S.C.A. § 1332 (West 1993 and West Supp. 1997).

In December 1996, the United States Food and Drug Administration (“FDA”) issued a memorandum recommending that all blood products or their derivatives intended for transfusion or injectable use should be retrieved and destroyed where a donor is diagnosed with CJD or is at increased risk for CJD.

On January 15,1997, Baxter transmitted a letter captioned “IMPORTANT DRUG WITHDRAWAL INFORMATION” to some of its customers, including Irvine, announcing *739 the immediate withdrawal of certain lots of Human Albumin. Baxter’s action was prompted by the discovery that two donors to the pool of plasma from which the lots were processed, were considered at risk for CJD as a result of post-donation information.

In early February 1997, the Does underwent in-vitro' fertilization treatment' at the Jones Institute for Women’s Health (“the Jones Institute”). Several eggs of an anonymous donor were fertilized in-vitro with sperm donated by John Doe. Three of the resulting embryos were transferred to the uterine cavity of Jane Doe and the remaining embryos were cryopreserved. The Human Albumin was used to store the sperm, eggs, and embryos during this process. As a result, the Does allege that the sperm, eggs, embryos and Jane Doe were all exposed to the Human Albumin subject to the withdrawal and potentially contaminated with CJD.

On February 27,1997, Irvine transmitted a “Product Withdrawal Notice” to some of its customers, including the Jones Institute, informing them of Baxter’s withdrawal of the • Albumin, and advising that they “immediately discontinue its use.”

On March 14, 1997, the Does learned that the embryo transfer did not result in a pregnancy and that they would have to transfer the remaining cryopreserved embryos. As a result of their exposure to the potentially, contaminated Albumin, the cryopreserved embryos were rendered not suitable for implantation.

The Does claim that Defendants knew, or should have known that certain lots of Human Albumin were potentially contaminated by Creutzfeldt-Jakob Disease (“CJD”)', which can cause a fatal neurological disorder in humans. It is the human equivalent of Bovine Spongiform Encephalopathy, commonly known as “Mad Cow Disease.” Science has not identified with certainty the infectious agent that causés CJD, however, experiments indicate that the agent of CJD may be transmittable by blood.

The Does allege that Defendants were negligent in their recall and withdrawal of the potentially contaminated Albumin from the market, and that such lots were used in connection with in-vitro fertilization and other assisted reproductive technology (“ART”) procedures. Specifically, Plaintiffs' allege that Baxter, “[flailed to withdraw the albumin, or warn of the dangers, when it first became aware that it might be contaminated with CJD ... [flailed to. ensure that the distributors of its Albumin product properly and timely cooperated with and performed the withdrawal ... and was otherwise negligent.” Pis.’ First Am. Compl. ¶ 40. Plaintiffs also allege that Baxter “negligently failed to warn its distributors, consumers and others in the stream of.commerce of the dangers of CJD contamination associated with the use of their Albumin.” Pis.’ First Am. Compl. ¶41. As to Irvine, Plaintiffs allege that it “failed to timely initiate and cooperate with Baxter’s withdrawal of the Albumin, or warn of the dangers, when it first became aware that it might be contaminated with CJD and that Baxter had initiated a withdrawal based upon FDA recommendations.” Pis.’ First Am. Compl. ¶ 42.

The Does contend that they would not have consented to the use of the Albumin subject to the withdrawal had they been informed of the possible CJD contamination, and that had the Jones Institute been informed of Baxter’s withdrawal of the Albumin, it would not have used the potentially contaminated lots in connection with ART procedures. The Does have never been offered compensation or reimbursement for their expenses associated with the ART procedures involving the Albumin. As a result, they claim that they and the members of the class have sustained and or may sustain personal injuries, property damage, emotional distress, and economic loss as a result of the Defendants’ actions. The Does seek monetary relief for compensatory and punitive damages.

The Does filed their Complaint and Motion for a Temporary Ex Parte Protective Order on December 16, 1997. Judge Smith of this court granted the Temporary Order on December 17, 1997. The Does filed their First Amended Complaint on February 12, 1998, adding a claim for intentional infliction of emotional distress.

*740 Baxter filed their Motion to Dismiss on February 17, 1998, and the Does responded on March 2, 1998. Baxter filed their Motion to Dismiss First Amended Complaint on March 9, 1998, and then replied to the Does’ response on March 18,1998.

Irvine filed their Motion to Dismiss Complaint and Motion to Dismiss First Amended Complaint on February 23, 1998. The Does responded on March 13, 1998, and Irvine replied on March 23,1998.

On May 5, 1998, the Court entered a Consent Order of Dismissal of the Does’ claim for intentional infliction of emotional distress with prejudice.

Concerning the Does’ Motion for Protective Order, Irvine responded on March 2, 1998. The Does replied on March 11, 1998, and on March, 18, 1998, they submitted an affidavit in support of their reply. These three filings remain under seal with the Court.

On May 7, 1998, the Court heard oral argument on Defendants’ Motions to Dismiss and Plaintiffs’ Motion for a Protective Order. Immediately after the hearing, counsel for the Does requested an opportunity to file a brief on the issue of the economic loss rule because Irvine raised the issue in its reply brief and on rebuttal at oral argument. Consequently, the Does had not had the opportunity to respond on this issue. The Court entered an Order permitting all parties to brief, within ten days, the economic loss rule issue. No reply briefs were allowed.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

F.G. v. CooperSurgical, Inc.
N.D. California, 2024
Crawford v. Deutsche Bank AG
244 F. Supp. 2d 615 (E.D. Virginia, 2003)

Cite This Page — Counsel Stack

Bluebook (online)
7 F. Supp. 2d 737, 1998 U.S. Dist. LEXIS 8741, 1998 WL 309217, Counsel Stack Legal Research, https://law.counselstack.com/opinion/doe-v-irvine-scientific-sales-co-inc-vaed-1998.